Vidac Pharma Holding PLC: Clinical Trial Approval in Germany Following CTIS Update

London (pta015/04.11.2025/10:28 UTC+1)

Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage biopharmaceutical company developing novel therapies for oncological and onco-dermatological indications, today announced that its clinical trial has been approved in Germany.

"This will be the first clinical trial specifically aimed at eliminating highly proliferative actinic keratosis (AK) lesions at risk of progressing to squamous cell carcinoma, a potentially metastatic cancer," said Dr. Eyal Breitbart, CTO of Vidac Pharma.

The approval follows a recent update in the Clinical Trials Information System (CTIS), marking another significant milestone in Vidac Pharma's ongoing clinical development program. This authorization enables the initiation of trial activities in Germany and further expands the company's European clinical footprint.

"We are honored and excited to receive authorization to begin this specific study in Germany," said Dr. Max Herzberg, Chairman and CEO of Vidac Pharma. "This would not have been possible without the scientific cooperation of Prof. Thomas Dirschka of Centroderm in Wuppertal and his team, and the in-depth work of all our collaborators both in-house and in Germany. This is an important step toward bringing our breakthrough therapies to patients across Europe. The Vidac team succeeded in creating new small molecules reversing, for the first time, the Warburg effect—a unique feature of all cancers discovered 100 years ago by Dr. Otto Warburg, the renowned German biochemist—and is now working toward new applications of this first-in-class, totally new mode of action."

"Vidac Pharma continues to collaborate closely with European regulatory authorities to ensure the highest standards of quality, safety, and compliance throughout its clinical development programs," declared Ms. Sandra Gamzon, MBA, Chief Operating Officer of Vidac Pharma.

For more information please contact:

About Vidac Pharma
Vidac Pharma is a clinical-stage biopharmaceutical company dedicated to discovering and developing first-in-class medicines to help people suffering from a range of oncologic and onco-dermatologic diseases. Vidac develops first-in-class anti-cancer drugs by modifying the hyper-glycolytic tumor microenvironment, targeting the overexpression and wrong anchoring of the Hexokinase 2 metabolic checkpoint (HK2) in cancer cells, to renormalize tumor microenvironment and selectively provoke their programmed death, without affecting surrounding normal tissue. VDA-1102, a first drug candidate of Vidac Pharma has shown to be effective against advanced Actinic Keratosis (AK), while interim results in Cutaneous T-cell Lymphoma (CTCL) yielded a positive effect in Phase 2 trials in humans.

Important information
The information in this press release does not constitute a public offer to sell or a solicitation to submit an offer to buy or subscribe to shares of Vidac Pharma Holding PLC, but is for informational purposes only. The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties, and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.

(end)

Emitter:	Vidac Pharma Holding PLC 20-22 Wenlock Road N1 7GU London United Kingdom
Contact Person:	Sandra Gamzon
Phone:	+972 544 999951
E-Mail:	investors@vidacpharma.com
Website:	www.vidacpharma.com
ISIN(s):	GB00BM9XQ619 (Share)
Stock Exchange(s):	Free Market in Berlin, Hamburg, Stuttgart